CARDAMYST Offers New Hope for PSVT Treatment: FDA Approves First Self-Administered Therapy

Milestone Pharmaceuticals Inc. has introduced CARDAMYST, marking a historic breakthrough for patients living with paroxysmal supraventricular tachycardia (PSVT). This represents the first FDA-approved self-administered PSVT treatment now available through U.S. retail pharmacies, fundamentally changing how patients manage this condition outside hospital settings.

Understanding PSVT: A Common Heart Rhythm Condition

More than two million Americans suffer from PSVT, a widespread heart rhythm disorder that can significantly impact daily life. The condition stems from an electrical abnormality in the heart that suddenly triggers rapid heart rate episodes, typically ranging from 160 to 220 beats per minute. Patients experiencing PSVT episodes often encounter distressing symptoms including heart palpitations, excessive sweating, chest pressure, shortness of breath, dizziness, and severe anxiety. Young adults are particularly susceptible to this condition, which can be triggered by intense physical activity. The unpredictable nature of PSVT episodes forces many patients to live with uncertainty and restrict their activities.

How CARDAMYST Transforms PSVT Treatment Options

CARDAMYST (etripamil), a rapid-acting nasal spray and calcium channel blocker, fundamentally changes the landscape of PSVT treatment. Previously, patients had no choice but to visit emergency departments for intravenous adenosine administration—a time-consuming and costly approach. Now, this innovative PSVT treatment enables patients to self-administer therapy during acute episodes from the comfort of their homes. This represents the first significant FDA-approved advancement in PSVT management in over three decades, offering unprecedented convenience and independence for patients. The shift from hospital-dependent acute care to home-based emergency management represents a major milestone in treating this common heart rhythm disorder.

Commercial Launch and Patient Accessibility

Milestone Pharmaceuticals is rolling out CARDAMYST with comprehensive patient support infrastructure. The company has established a patient assistance program providing benefits verification, reimbursement navigation, and copay assistance. Eligible commercially insured patients can expect copays capped at $25, making this PSVT treatment more financially accessible. Milestone continues engaging with insurance providers regarding coverage and formulary positioning. This commercial transition marks a significant evolution for Milestone Pharmaceuticals as it shifts from a clinical-stage enterprise to an established commercial organization delivering real-world solutions for PSVT patients.